Compare Stocks: ORGO, ACRS, DBVT, and FDMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.53 -2.0%	$5.81	$1.74 ▼ $6.60	$773.21M	0.79	1.96 million shs	1.33 million shs
DBVT DBV Technologies	$11.76 -4.8%	$14.22	$8.85 ▼ $26.18	$739.47M	-0.95	304,137 shs	174,873 shs
FDMT 4D Molecular Therapeutics	$13.63 -0.9%	$12.66	$6.47 ▼ $16.93	$752.98M	2.74	825,948 shs	550,944 shs
ORGO Organogenesis	$1.46 -2.7%	$2.06	$1.45 ▼ $7.08	$187.87M	1.29	1.03 million shs	445,069 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+6.02%	-8.59%	-2.42%	+29.95%	+189.23%
DBVT DBV Technologies	+4.22%	-8.31%	-11.91%	-26.27%	+25.13%
FDMT 4D Molecular Therapeutics	+4.48%	-8.08%	+12.88%	+58.71%	+102.06%
ORGO Organogenesis	+0.67%	-12.28%	-16.20%	-37.50%	-69.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.53 -2.0%	$5.81	$1.74 ▼ $6.60	$773.21M	0.79	1.96 million shs	1.33 million shs
DBVT DBV Technologies	$11.76 -4.8%	$14.22	$8.85 ▼ $26.18	$739.47M	-0.95	304,137 shs	174,873 shs
FDMT 4D Molecular Therapeutics	$13.63 -0.9%	$12.66	$6.47 ▼ $16.93	$752.98M	2.74	825,948 shs	550,944 shs
ORGO Organogenesis	$1.46 -2.7%	$2.06	$1.45 ▼ $7.08	$187.87M	1.29	1.03 million shs	445,069 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+6.02%	-8.59%	-2.42%	+29.95%	+189.23%
DBVT DBV Technologies	+4.22%	-8.31%	-11.91%	-26.27%	+25.13%
FDMT 4D Molecular Therapeutics	+4.48%	-8.08%	+12.88%	+58.71%	+102.06%
ORGO Organogenesis	+0.67%	-12.28%	-16.20%	-37.50%	-69.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	104.94% Upside
DBVT DBV Technologies	2.57	Moderate Buy	$48.50	312.41% Upside
FDMT 4D Molecular Therapeutics	2.82	Moderate Buy	$28.56	109.51% Upside
ORGO Organogenesis	1.67	Reduce	$4.33	196.80% Upside

Current Analyst Ratings Breakdown

Latest ORGO, ACRS, DBVT, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	FDMT 4D Molecular Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$20.00
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/4/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/21/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/7/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	ORGO Organogenesis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$3.00 ➝ $2.00
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	98.75	N/A	N/A	$0.85 per share	6.51
DBVT DBV Technologies	$5.64M	131.11	N/A	N/A	$4.20 per share	2.80
FDMT 4D Molecular Therapeutics	$92.01M	8.18	N/A	N/A	$8.85 per share	1.54
ORGO Organogenesis	$564.17M	0.33	$0.63 per share	2.30	$2.36 per share	0.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	11/5/2026 (Estimated)

Latest ORGO, ACRS, DBVT, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
DBVT DBV Technologies	N/A	3.72	3.72
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
ORGO Organogenesis	0.07	3.52	3.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
DBVT DBV Technologies	71.74%
FDMT 4D Molecular Therapeutics	99.27%
ORGO Organogenesis	49.57%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
DBVT DBV Technologies	1.06%
FDMT 4D Molecular Therapeutics	7.90%
ORGO Organogenesis	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	73	139.82 million	133.11 million	Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
FDMT 4D Molecular Therapeutics	196	55.24 million	50.88 million	Optionable
ORGO Organogenesis	854	128.68 million	104.48 million	Optionable

ORGO, ACRS, DBVT, and FDMT Headlines

Recent News About These Companies

BlackRock Inc. Purchases Shares of 7,249,528 Organogenesis $ORGO

September 4, 2026 | marketbeat.com

Organogenesis stock trades without a fresh catalyst, recent results define the picture

August 29, 2026 | ad-hoc-news.deA

Deutsche Bank AG Purchases New Shares in Organogenesis $ORGO

August 26, 2026 | marketbeat.com

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Organogenesis forecasts 2026 revenue of $179M-$215M amid June restructuring expected to cut $18M annually

August 8, 2026 | seekingalpha.com

Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Organogenesis Launches New $75 Million At-The-Market Offering

August 6, 2026 | tipranks.com

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

August 6, 2026 | globenewswire.com

Organogenesis Announces Published RCT Results Showing Affinity Plus Standard of Care Improves Closure Rates in Complex Venous Leg Ulcers

July 27, 2026 | quiverquant.comQ

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

July 27, 2026 | globenewswire.com

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

July 9, 2026 | globenewswire.com

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

July 6, 2026 | globenewswire.com

Organogenesis Stockholders Reelect Board and Approve Governance Items

June 16, 2026 | tipranks.com

Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked

June 15, 2026 | seekingalpha.com

Organogenesis Earnings Call: Deep Pain, Long Road

June 7, 2026 | theglobeandmail.com

Truist Securities initiates coverage of Organogenesis Holdings (ORGO) with hold recommendation

May 29, 2026 | msn.com

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

May 22, 2026 | finance.yahoo.com

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

May 20, 2026 | insidermonkey.com

Organogenesis (ORGO) Q1 2026 Earnings Transcript

May 8, 2026 | fool.com

Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

May 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ORGO, ACRS, DBVT, and FDMT Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$5.53 -0.11 (-1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$5.37 -0.16 (-2.97%)

As of 04:43 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

DBV Technologies NASDAQ:DBVT

$11.76 -0.59 (-4.78%)

Closing price 04:00 PM Eastern

Extended Trading

$11.88 +0.12 (+1.02%)

As of 04:37 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

4D Molecular Therapeutics NASDAQ:FDMT

$13.63 -0.13 (-0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$13.64 +0.01 (+0.07%)

As of 04:38 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Organogenesis NASDAQ:ORGO

$1.46 -0.04 (-2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$1.45 -0.01 (-0.68%)

As of 04:15 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, ACRS, DBVT, and FDMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, ACRS, DBVT, and FDMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, ACRS, DBVT, and FDMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ORGO, ACRS, DBVT, and FDMT Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

4D Molecular Therapeutics NASDAQ:FDMT

Organogenesis NASDAQ:ORGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, ACRS, DBVT, and FDMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, ACRS, DBVT, and FDMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, ACRS, DBVT, and FDMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ORGO, ACRS, DBVT, and FDMT Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

4D Molecular Therapeutics NASDAQ:FDMT

Organogenesis NASDAQ:ORGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools